Clinical Trial: Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous SPL-108 Injections When Used In Combination With Paclitaxel In Patients With Platinum-resistant, CD44+, Advanced

Brief Summary: Up to 18 women with ovarian cancer will administer up to two injections of SPL-108 daily in combination with weekly doses of Paclitaxel. They will be monitored for safety and efficacy for up to 6 months, until disease progression or unacceptable toxicity.

Detailed Summary:

This is an open-label 2-arm trial. Eligible subjects will be screened and enrolled sequentially into 1 of 2 Arms:

Arm I: N=6 to 12 subjects, Safety Phase

  • Cohort 1 SPL-108 x 1 injection daily + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles
  • Cohort 2 SPL-108 BID + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles

For Arm I, at least 1 week will elapse between Dose 1 for each subject.

In Cohort 1, 3 subjects will be enrolled: if 1 dose-limiting toxicity (DLT) occurs, 3 subjects will be added at this dose level; if 0/3 or 1/6 DLTs occur, Cohort 2 will initiate enrolling subjects; if 2 or more DLTs occur at this dose level, subjects will not be enrolled in Cohort 2 and the trial will be terminated.

In Cohort 2, 3 subjects will be enrolled: if 1 DLT occurs, 3 subjects will be added at this dose level; if 0/3 or 1/6 DLTs occur, Arm II will initiate enrolling subjects at the SPL-108 BID dose; if 2 or more DLTs occur, Arm II will initiate enrolling subjects at the SPL-108 dose one time each day.

Arm II: N=up to 12, Exploratory Expansion Phase

• Cohort 3: SPL-108 daily dose (to be determined in Arm I) + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles.

A Safety Committee will meet at the end of each Arm I Cohort as well as periodically to review safety data and make recommendations for trial progression. The primary efficacy outcome, Response Evaluation Criteria in Solid Tumors Committee (RECIST 1.1) criteria, will be assessed on Da
Sponsor: Splash Pharmaceuticals, Inc.

Current Primary Outcome: Incidence of Adverse Events (Safety) [ Time Frame: Until dose-limiting toxicity, disease progression or 6 months ]

Includes adverse events, laboratory data, physical examination findings, vital signs, weight and ECOG Performance Status


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Response to Investigational Product [ Time Frame: Until dose-limiting toxicity, disease progression or 6 months ]
    Objective response (OR) through imaging assessments
  • Response to Investigational Product [ Time Frame: Until dose-limiting toxicity, disease progression or 6 months ]
    Objective response (OR) through changes in CA 125 levels
  • Response to Investigational Product [ Time Frame: Until dose-limiting toxicity, disease progression or 6 months ]
    Objective response (OR) as assessed through changes in Quality of Life (FACT-O Questionnaire)


Original Secondary Outcome: Same as current

Information By: Splash Pharmaceuticals, Inc.

Dates:
Date Received: March 4, 2017
Date Started: April 2017
Date Completion: December 31, 2018
Last Updated: April 24, 2017
Last Verified: April 2017